IQVIA Holdings Inc. — News

Amundi lowered its holdings in shares of IQVIA Holdings Inc. (NYSE: IQV) by 19.2% in the first quarter, according to its most recent disclosure with the SEC. The firm owned 869,003 shares of the medical research company's stock after selling 206,218 shares during the period. Amundi owned 0.52% of IQVIA worth $148,200,000 as

defenseworld.net - 2026-08-01 04:21:39

FHLC's 0.08% expense ratio and market-cap approach delivered stronger returns, while RSPH's equal-weight strategy offers lower volatility and broader diversification across 60 holdings.

fool.com - 2026-07-31 10:55:36

IQVIA Holdings Inc. operates behind the scenes, running clinical trials and processing vast healthcare data for pharmaceutical companies. IQV's business spans clinical trial management, healthcare data analytics, software products, and consulting, providing diversified revenue streams. I previously rated IQV a Buy due to strong results and robust demand, but concerns over slowing guidance, CSMS segment weakness, and regulatory risks tempered my enthusiasm.

seekingalpha.com - 2026-07-29 09:59:50

The headline numbers for IQVIA (IQV) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

zacks.com - 2026-07-28 22:31:09

IQVIA Holdings Inc. (IQV) Q2 2026 Earnings Call Transcript

seekingalpha.com - 2026-07-28 16:23:14

IQVIA NYSE: IQV reported second-quarter results that exceeded the high end of its guidance, supported by accelerating organic revenue growth, higher R&D Solutions bookings and operational productivity gains. The company also raised its full-year outlook for revenue, adjusted EBITDA and adjusted diluted earnings per share.

marketbeat.com - 2026-07-28 15:05:46

IQVIA Holdings leads the index after the company boosted its full-year outlook on the back of a strong second quarter.

barrons.com - 2026-07-28 12:44:00

IQVIA's Q2 earnings beat estimates as record R&D bookings, broad-based growth and stronger demand support a raised 2026 outlook.

zacks.com - 2026-07-28 11:41:12

IQVIA Holdings (IQV) came out with quarterly earnings of $3.15 per share, beating the Zacks Consensus Estimate of $3.02 per share. This compares to earnings of $2.81 per share a year ago.

zacks.com - 2026-07-28 09:16:07

IQVIA Holdings raised its annual profit forecast on Tuesday after reporting better-than-expected second-quarter results, driven by strong ​demand for its healthcare data and analytics services, ‌sending its shares up 11% before the bell.

reuters.com - 2026-07-28 09:02:38

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today reported financial results for the quarter ended June 30, 2026. Year-Over-Year Comparisons As previously disclosed, effective January 1, 2026, the company implemented a new, simplified organizational model to strengthen collaboration, enhance efficien.

businesswire.com - 2026-07-28 07:00:00

Castleark Management LLC bought a new position in IQVIA Holdings Inc. (NYSE: IQV) in the undefined quarter, according to its most recent disclosure with the SEC. The firm bought 22,580 shares of the medical research company's stock, valued at approximately $3,851,000. Several other hedge funds and other institutional investors also recently modified their

defenseworld.net - 2026-07-28 04:09:58

Dai ichi Life Insurance Company Ltd decreased its holdings in IQVIA Holdings Inc. (NYSE: IQV) by 34.1% in the undefined quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 7,723 shares of the medical research company's stock after selling 4,000 shares during the quarter. Dai ichi

defenseworld.net - 2026-07-27 03:56:08

Arrowstreet Capital Limited Partnership raised its stake in IQVIA Holdings Inc. (NYSE: IQV) by 3.1% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 992,190 shares of the medical research company's stock after acquiring an additional 30,051 shares during the quarter.

defenseworld.net - 2026-07-25 03:43:24

IQV heads into its Q2'26 earnings release with y/y revenue and EPS growth expected, supported by AI adoption, drug launches and high-margin segment gains.

zacks.com - 2026-07-24 13:56:05

IQVIA (IQV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

zacks.com - 2026-07-21 11:00:46

Andra AP fonden raised its stake in IQVIA Holdings Inc. (NYSE: IQV) by 320.1% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 121,405 shares of the medical research company's stock after purchasing an additional 92,505 shares during the quarter. Andra AP fonden

defenseworld.net - 2026-07-21 03:58:03

Cantillon Capital Management LLC lowered its position in IQVIA Holdings Inc. (NYSE: IQV) by 11.9% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,710,896 shares of the medical research company's stock after selling 230,248 shares during the

defenseworld.net - 2026-07-20 05:08:47

California Public Employees Retirement System increased its holdings in IQVIA Holdings Inc. (NYSE: IQV) by 2.0% during the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 337,191 shares of the medical research company's stock after buying an additional 6,563 shares during the period. California Public Employees

defenseworld.net - 2026-07-20 04:27:42

I identify dividend stocks and REITs that could protect investors from AI bubble risks, geopolitics, and inflation while generating attractive income. My "ALLKA Dividend Rating" model separates quality dividend opportunities from yield traps by analyzing dividend sustainability, growth prospects, and valuation. The article explores three dividend strategies, "High-Yield Defensive," "Balanced Income," and "Pure Growth," designed for goals ranging from high yield to dividend growth.

seekingalpha.com - 2026-07-18 13:03:19

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, shared recommendations for strengthening the United States as a leading destination for early clinical development during the U.S. House Committee on Energy and Commerce Subcommittee on Health hearing, “Maintaining America's Leadership in Biomedical Innovation: FDA's Role in Advan.

businesswire.com - 2026-07-16 13:39:00

Investors interested in stocks from the Medical - Instruments sector have probably already heard of IQVIA Holdings (IQV) and Penumbra (PEN). But which of these two stocks is more attractive to value investors?

zacks.com - 2026-07-14 12:40:26

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

zacks.com - 2026-07-09 10:41:34

IQVIA's AI tools, record R&D backlog and strong free cash flow support its outlook, but weak liquidity and no dividend remain investor concerns.

zacks.com - 2026-07-03 09:55:46

TORONTO--(BUSINESS WIRE)--StackAdapt (www.stackadapt.com), the leading AI advertising and orchestration platform, today announced a collaboration with IQVIA Digital to advance more relevant and compliant engagement with healthcare audiences. IQVIA Digital's integrated solutions enable marketers to quickly transform data-driven insights into meaningful, privacy-conscious activation across the healthcare ecosystem.Through this collaboration, StackAdapt's programmatic advertising capabilities are n.

businesswire.com - 2026-06-18 10:17:00

In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.

forbes.com - 2026-06-17 12:30:08

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

zacks.com - 2026-06-17 10:40:16

Futures are trading mixed as we hit the midweek point, as the Space Exploration Technologies (NASDAQ: SPCX) or SpaceX IPO rush is starting to fade somewhat.

247wallst.com - 2026-06-17 08:00:44

IQVIA Holdings gains from its vast healthcare data, AI-driven analytics & global IT infrastructure, supporting expansion and solid growth.

zacks.com - 2026-06-15 12:17:31

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

zacks.com - 2026-06-15 10:50:44

Wiley (NYSE: WLY) and IQVIA (NYSE: IQV) today released [url="]Scientific Discovery and AI: The Science-to-Patient Journey[/url], a cross-sector intelligence repo

gurufocus.com - 2026-06-15 10:00:00

HOBOKEN, N.J.--(BUSINESS WIRE)--Wiley (NYSE: WLY) and IQVIA (NYSE: IQV) today released Scientific Discovery & AI: The Science-to-Patient Journey, a cross-sector intelligence report drawing on candid dialogue among more than 25 senior leaders from pharma R&D, academic medicine, health systems, AI and technology, publishing and learned societies. The report summarizes insights from The Summit — an invitation-only, two-day working session co-hosted by Wiley and IQVIA in May 2026. The sessi.

businesswire.com - 2026-06-15 09:00:00

IQVIA (IQV) reported earnings 30 days ago. What's next for the stock?

zacks.com - 2026-06-04 12:36:32

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) today announced that its wholly owned subsidiary, IQVIA Inc. (the “Issuer”), priced an offering of €950,000,000 in aggregate principal amount of senior notes due 2033 (the “Notes”). The proceeds from the Notes offering will be used to refinance certain of the Issuer's existing indebtedness and to pay fees and expenses related to the Notes offering. The Notes will bear interest at a rate of 4.625% per annum a.

businesswire.com - 2026-06-04 10:51:00

IQVIA Holdings Inc. (IQV) Presents at Jefferies Global Healthcare Conference 2026 Transcript

seekingalpha.com - 2026-06-03 11:22:05

IQVIA Holdings Inc. (“IQVIA”) (NYSE: IQV) today announced that its wholly owned subsidiary, IQVIA Inc. (the “Issuer”), intends to raise €950,000,000 t

gurufocus.com - 2026-06-03 03:00:00

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) today announced that its wholly owned subsidiary, IQVIA Inc. (the “Issuer”), intends to raise €950,000,000 through an offering of senior notes due 2033 (the “Notes”). The proceeds from the Notes offering will be used to refinance certain of the Issuer's existing indebtedness and to pay fees and expenses related to the Notes offering. The consummation of the Notes offering is subject to market and other custo.

businesswire.com - 2026-06-03 02:53:00

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

zacks.com - 2026-06-01 10:42:30

VEEV and IQV are benefiting from life sciences digitization trends, but differences in growth, AI adoption and valuation set them apart.

zacks.com - 2026-05-29 12:16:06

IQVIA's record $34.2B backlog, AI-led pharma demand and $1.24B buybacks support growth despite weak liquidity and no dividend.

zacks.com - 2026-05-27 13:01:21

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

zacks.com - 2026-05-26 10:51:15

IQVIA earns a Buy rating as the market underappreciates its AI-driven Commercial Solutions segment and unique healthcare data assets. AI is a tailwind, not a threat, with 19 of the top 20 pharma companies using IQV's AI agents and workflows. Commercial Solutions segment grew 11.6% year-over-year, outpacing the traditional CRO segment and driving margin expansion.

seekingalpha.com - 2026-05-20 12:05:32

Our top-performing stocks this quarter were Samsung Electronics, Shell and Lam Research. Our worst contributors were IQVIA, American Express and Heidelberg. We exited our investments in Everest Group and PayPal during the quarter.

seekingalpha.com - 2026-05-19 08:40:00

Valvoline was Broyhill's largest contributor in the quarter, as the underlying unit economics are intact, while unit growth, service mix, and price continue moving in the same direction. Honeywell management accelerated the aerospace spin-off to the end of June, leaving behind a pure-play automation business that Broyhill believes is worth meaningfully more than the whole. Large pharma is structurally reliant on IQVIA's clinical trial architecture and proprietary data assets, and Broyhill thinks it is highly unlikely that AI can automate away the FDA approval process.

seekingalpha.com - 2026-05-15 02:55:00

IQVIA Holdings Inc. (IQV) Presents at Bank of America Global Healthcare Conference 2026 Transcript

seekingalpha.com - 2026-05-13 16:40:48

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

zacks.com - 2026-05-12 10:41:24

IQVIA NYSE: IQV reported record first-quarter revenue and adjusted diluted earnings per share for 2026, with management citing accelerating organic growth across its Commercial Solutions and R&D Solutions businesses, increased demand tied to artificial intelligence offerings and continued strength in forward-looking clinical development metrics.

marketbeat.com - 2026-05-11 00:06:14

The headline numbers for IQVIA (IQV) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

zacks.com - 2026-05-06 10:30:38

We initiated four new positions in Q1, an above-average pace of activity. We also used the increased volatility to upgrade overall portfolio quality. Our three largest new positions were Amazon.com, Universal Music Group and IQVIA Holdings. In addition to sales of Humana and PayPal, we also exited our positions in social technology leader Meta Platforms and beverages company Diageo.

seekingalpha.com - 2026-05-06 00:34:00

IQVIA Holdings Inc. (IQV) Q1 2026 Earnings Call Transcript

seekingalpha.com - 2026-05-05 16:31:27